Renal Diseases - High Degree of Innovation and Diversity with Products Targeting Immune and Hormone Signaling Dominating the Pipeline for Chronic Kidney Disease, Frontier Pharma (Research and Other)

"Frontier Pharma: Renal Diseases - High Degree of Innovation and Diversity with Products Targeting Immune and Hormone Signaling Dominating the Pipeline for Chronic Kidney Disease" The Report covers current Industries Trends, Worldwide Analysis, Global Forecast, Review, Share, Size, Growth, Effect.
. .
Description-
' '
– The renal diseases therapy area encompasses a range of diseases of the kidney, such as chronic kidney disease (CKD), acute kidney injury, diabetic nephropathy and focal segmental glomerulosclerosis. Renal diseases are becoming increasingly common due to the increased prevalence of hypertension and diabetes, two major causes of CKD. For most forms of renal diseases, early detection and management may slow down or prevent progression to renal failure and associated complications. However, many renal diseases are typically asymptomatic until they have progressed to end-stage renal disease (ESRD), which requires renal replacement therapies such as hemodialysis and renal transplantation, and is associated with substantial morbidity and mortality.
. .
Get Sample Report @ https://www.researchmoz.us/enquiry.php?type=S&repid=1370888
' '
– The marketed treatments of renal diseases typically focus on controlling the risk factors and complications of renal failure. Treatments include anti-hypertensive agents, hormones, antibiotics, and immunosuppressants. However, these treatments are often not wholly effective, as patients are still at risk of dying prematurely from cardiovascular disease or progressing to ESRD. Few new renal disease therapies have reached the market in the past decade, and with the rising prevalence, there is a high need for innovation and investment in the renal diseases therapy area.

– The report assesses first-in-class innovation in the renal diseases pipeline, highlighting key trends and emerging treatment classes. There are 100 first-in-class products in development in this therapy area, which account for 39% of products in the overall pipeline for which there is a disclosed molecular target, and act upon 77 unique individual molecular targets. First-in-class innovation is concentrated heavily at the early drug development stages.
– The first-in-class programs identified show considerable diversity, and the relatively high degree of innovation in the renal diseases therapy area makes for a promising development pipeline. It is clear that recent activity in this area has increased, partly owing to the growing recognition of the unmet medical need. Further investment in innovation would benefit the therapy area greatly, and likely prove a worthwhile investment, particularly for highly prevalent diseases such as CKD and diabetic nephropathy, for which there are a lack of effective pharmacotherapeutic options.

– – Scope– –

- With 365 products in active development, the pipeline is modestly sized. Does current pipeline innovation hold the potential to affect the future renal diseases market?
- There are 100 first-in-class products in the renal diseases pipeline. Which of these hold the greatest potential to improve future disease treatment with regard to their molecular target?
- The majority of first-in-class products were in development for indications involving inflammation. Which first-in-class targets are most promising, and how does the ratio of first-in-class targets to first-in-class products differ by stage of development and molecular target class?
- A significant number of first-in-class products have been identified with no prior involvement in deals. How do deal frequency and value compare between target families and molecule types, and which first-in-class programs have not yet been involved in a licensing or co-development deal?

– – Reasons to buy– –

- Understand the current clinical and commercial landscape. It includes a comprehensive study of disease pathogenesis, diagnosis, prognosis and the treatment options available.
- Visualize the composition of the renal diseases market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the current market.
- Analyze the renal diseases pipeline and stratify by stage of development, molecule type and molecular target. There are strong signs in the pipeline that the industry is seeking novel approaches to treating renal diseases to overcome the level of unmet need.
- Assess the therapeutic potential of first-in-class targets. Using proprietary matrices, first-in-class products have been assessed and ranked according to clinical potential. The matrices have been split into three categories: renal failure, glomerulonephritides, and renal scarring. Promising targets have been reviewed in greater detail.
- Identify commercial opportunities in the renal diseases deals landscape by analyzing trends in licensing and co-development deals, and producing a list of first-in-class therapies with no prior involvement in licensing or co-development deals
. .
More Clear Details get Table of Contents @ https://www.researchmoz.us/frontier-pharma-renal-diseases-high-degree-of-innovation-and-diversity-with-products-targeting-immune-and-hormone-signaling-dominating-the-pipeline-for-chronic-kidney-disease-report.html/toc

ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Researchmoz Global Pvt. Ltd.
90 State Street,
Albany, NY 12207,
United States,
Tel: 866-997-4948 (Us-Canada Toll Free),
Tel: +1-518-621-2074

This release was published on openPR.